Overview

• The BaxHTN Phase 3 trial enrolled patients on two antihypertensive drugs and those with resistant hypertension on three or more therapies, including a diuretic.
• Both 1 mg and 2 mg doses of baxdrostat achieved statistically significant and clinically meaningful reductions in mean seated systolic blood pressure at 12 weeks versus placebo.
• All secondary endpoints were met and baxdrostat demonstrated a generally well-tolerated safety profile across study participants.
• AstraZeneca will share full data with regulatory authorities worldwide and present detailed findings at the ESC Congress in August 2025.
• Ongoing pivotal trials in patients with primary aldosteronism aim to confirm long-term efficacy and bolster future approval filings.